Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abciximab

Next Previous
X
Search
Drug Profile

Abciximab

Alternative Names: c7E3; CentoRx; Centrex; ClearWay®RX/abciximab; Monoclonal antibody 7E3; ReoPro

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centocor
  • Developer Centocor; Eli Lilly and Company; Janssen Biotech
  • Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis; Unstable angina pectoris
  • Discontinued Arterial occlusive disorders; Myocardial infarction; Stroke

Most Recent Events

  • 03 May 2013 Final efficacy data from the INFUSE-AMI phase III trial in Myocardial infarction (new drug delivery system) released by Atrium Medical Corporation
  • 30 Apr 2012 Launched for Coronary artery restenosis in Ireland (IV)
  • 25 Nov 2011 Launched for Coronary artery restenosis in Russia (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top